Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

(GNCA)

(GNCA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6
  • Shares Outstanding, K 58,730
  • Annual Sales, $ 1,640 K
  • Annual Income, $ -33,200 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.61
  • Price/Sales 0.02
  • Price/Cash Flow N/A
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings N/A on 05/05/22
  • Next Earnings Date 12/29/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Most Recent Stories

More News
Genocea Announces Wind Down of Operations and Delisting From NASDAQ

CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...

GNCA : 0.0001 (unch)
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...

GNCA : 0.0001 (unch)
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

    GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and...

GNCA : 0.0001 (unch)
Genocea Biosciences to Host Investor Webinar

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...

GNCA : 0.0001 (unch)
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation...

GNCA : 0.0001 (unch)
Genocea Provides Fourth Quarter 2021 Corporate Update

Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE)...

GNCA : 0.0001 (unch)
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors...

GNCA : 0.0001 (unch)
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors

CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...

GNCA : 0.0001 (unch)
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation...

GNCA : 0.0001 (unch)
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation...

GNCA : 0.0001 (unch)

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 0.0001
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.0001
Fibonacci 61.8% 0.0001
Fibonacci 50% 0.0001
Fibonacci 38.2% 0.0001
Last Price 0.0001
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar